HYPREVENTION
Hyprevention has raised new financing to support the V-STRUT© Vertebral Implant product. The financing will be used to execute the commercialization plans for the US spinal fracture market. The V-STRUT© Vertebral Implant is indicated for use in the treatment of vertebral fractures. In May 2019, a US patent was granted for V-STRUT© and in March 2020, the device received FDA-510(k) clearance.
“We are delighted that our existing investors have shown confidence in our product development efforts and commercialization plans for the US market by increasing their investment in the company,” says Cecile Vienney, CEO.
The Hyprevention team has entered into a commercial relationship with DAWA Medical and has received several orders for the product from enthusiastic customers. DAWA Medical, a regional distributor of medical products, will promote sales in Florida, Illinois, Texas and Oklahoma. In addition to DAWA the company is in discussion with other commercial partners to bring the innovative V-STRUT© product to the US spinal injury market.
About V-STRUT©
V-STRUT© Vertebral Implant is an implantable medical device made of INVIBIO PEEK Optima® polymer indicated for use in the treatment of vertebral fractures in the thoracic and lumbar spine. It is intended to be used in combination with Teknimed F20® bone cement. V-STRUT© is patented and cleared in the USA. The device was developed with the support of Key Opinion Leaders in the spine surgery. A deep literature review allowed to identify unmet clinical needs such as subsequent and adjacent fractures after treatment in osteoporotic and cancer patients. The device was developed to address this clinical need thanks to its soft material, close to normal bone, and an unique pedicle anchorage.
About Hyprevention
Hyprevention was founded in 2010 in France by 3 orthopedic and spine surgeons and an experimented Executive Team. The company aims to develop innovative products addressing bone fragility as the consequence of osteoporosis and bone metastasis, thanks to the unique technique STRUTPLASTY® intended to reinforce the bone with polymer implant combined with bone cement.
About DAWA Medical
DAWA Medical is a master distributor for the USA and Canada. DAWA acts as US Agent, Initial Importer, warehousing and shipping. The company has a large network of distributors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200928005423/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yokogawa Collaborates with Shell on Robotics and AI Technology for Plant Maintenance18.6.2025 08:00:00 CEST | Press release
- Streamlining operations and reducing risk in asset integrity management – Yokogawa Electric Corporation (TOKYO: 6841) announces that it has formalized a long-term agreement with Shell Global Solutions International B.V. (“Shell”) to integrate and further develop technologies for utilizing robots and drones in plant monitoring and maintenance. Under the agreement, Yokogawa will add an advanced machine vision tool called Operator Round by Exception (ORE), developed by Shell, into its own OpreX™ Robot Management Core. The enhanced software service will be made available by Yokogawa to customers in the energy, chemicals, and other industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617976629/en/ OpreX Robot Management Core ORE is a digital solution that uses machine vision and AI analytics to enable robots to autonomously perform a number of tasks in the operator round process, such as reading gauges and checking for
Ververica Announces Partnership with Aiven - Empowering Leading Enterprises to Create Value from their Data in Real-Time18.6.2025 08:00:00 CEST | Press release
Ververica, the original creators of Apache Flink® and a leader in stream processing technology, today announced a new partnership with Aiven, the AI-ready open source cloud data platform. This partnership enables Aiven to provide Ververica’s Unified Streaming Data Platform to their customers, expanding access to enterprise-grade streaming data capabilities for data-driven businesses around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617806011/en/ Ververica Announces Partnership with Aiven - Empowering Leading Enterprises to Create Value from their Data in Real-Time Under the partnership, Aiven customers can now unlock enterprise-grade stream processing with Ververica’s powerful platform — allowing them to make decisions and take actions at speed with data from any source — plus expert support from the original creators of Apache Flink. “This partnership is about removing friction and delivering real business
ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years18.6.2025 07:00:00 CEST | Press release
An interim analysis of the OLYMPIA long-term extension study to be presented as a late-breaking abstract at the XIV International Congress of Dermatology (ICD) found that Nemluvio was well tolerated and associated with sustained and clinically meaningful improvements in the key signs and symptoms of prurigo nodularis, including both skin lesions and itch, up to two years1 Results build on data from OLYMPIA – the largest completed pivotal clinical program in prurigo nodularis and the only one assessing long-term safety and efficacy in prurigo nodularis1-3 This follows the presentation of data from the ARCADIA long-term extension study at the Revolutionizing Atopic Dermatitis (RAD) Conference earlier this month, which showed Nemluvio is well tolerated with sustained and increased improvements in efficacy outcomes in atopic dermatitis patients up to two years4 Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy o
LabPMM® Receives New York State Approval for the NPM1 MRD Assay - Informing Therapy and Accelerating Targeted Trials18.6.2025 06:30:00 CEST | Press release
Invivoscribe is happy to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM) has received approval from New York State (NYS) for the NPM1 MRD Assay. This approval comes just two months after gaining NYS approval for our FLT3 ITD MRD Assay. Together these tests represent a critical tool for patients with acute myeloid leukemia (AML), clinicians and pharmaceutical companies. This new approval underscores Invivoscribe’s ongoing commitment to providing the most accurate, standardized measurable residual disease (MRD) testing solutions worldwide. The NPM1 MRD Assay is a pivotal development in the fight against AML, offering an ultra-sensitive DNA sequencing method to accurately measure trace levels of residual leukemia cells in patients with the NPM1 mutation variants. NPM1 mutations are considered an ideal target for MRD assessment because they are present in ~30% of adult AML cases,1 stable over time,2 and, if present in blood at allele
DNP to Take Controlling-Stake in Laxton18.6.2025 03:30:00 CEST | Press release
Maximizing synergies to accelerate the global expansion of biometric info-driven government authentication and security business Dai Nippon Printing Co., Ltd. (DNP, TOKYO: 7912) entered into a share transfer agreement on June 17, 2025 to acquire Cayman Islands-headquartered Rubicon SEZC. Rubicon (a holding company of “Laxton” group) is a global Identity Systems Integrator that provides ID solutions for governments, primarily in developing nations, to register and authenticate personal information. DNP plans to acquire 75% of Rubicon's shares in July and complete the procedures to make the company a Group company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250613922077/en/ Products of Laxton DNP will maximize synergies with Laxton in ID cards and card printers. By expanding to government-related business in Africa, Asia, South America, and other regions, we will further grow our authentication and security business, contr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom